Sarepta’s DMD Gene Therapy: Approval Delayed And Indication Narrowed, But Still On Track

 
• By Derrick Gingery
  
delay sign
Accelerated approval is expected in boys age four to five at first, but could grow pending the results of the EMBARK trial. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies